116 related articles for article (PubMed ID: 34520770)
41. Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells.
Jin Q; Yuan LX; Boulbes D; Baek JM; Wang YN; Gomez-Cabello D; Hawke DH; Yeung SC; Lee MH; Hortobagyi GN; Hung MC; Esteva FJ
Breast Cancer Res; 2010; 12(6):R96. PubMed ID: 21080941
[TBL] [Abstract][Full Text] [Related]
42. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J
Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618
[TBL] [Abstract][Full Text] [Related]
43. Imidazo[1,2-a]pyrazine diaryl ureas: inhibitors of the receptor tyrosine kinase EphB4.
Mitchell SA; Danca MD; Blomgren PA; Darrow JW; Currie KS; Kropf JE; Lee SH; Gallion SL; Xiong JM; Pippin DA; DeSimone RW; Brittelli DR; Eustice DC; Bourret A; Hill-Drzewi M; Maciejewski PM; Elkin LL
Bioorg Med Chem Lett; 2009 Dec; 19(24):6991-5. PubMed ID: 19879134
[TBL] [Abstract][Full Text] [Related]
44. HER2 Upregulates ATF4 to Promote Cell Migration via Activation of ZEB1 and Downregulation of E-Cadherin.
Zeng P; Sun S; Li R; Xiao ZX; Chen H
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31064130
[TBL] [Abstract][Full Text] [Related]
45. PET imaging of colorectal and breast cancer by targeting EphB4 receptor with 64Cu-labeled hAb47 and hAb131 antibodies.
Liu S; Li D; Park R; Liu R; Xia Z; Guo J; Krasnoperov V; Gill PS; Li Z; Shan H; Conti PS
J Nucl Med; 2013 Jul; 54(7):1094-100. PubMed ID: 23667241
[TBL] [Abstract][Full Text] [Related]
46. Desacetyl nimbinene inhibits breast cancer growth and metastasis through reactive oxygen species mediated mechanisms.
Arumugam A; Subramani R; Nandy S; Powell S; Velazquez M; Orozco A; Galvez A; Lakshmanaswamy R
Tumour Biol; 2016 May; 37(5):6527-37. PubMed ID: 26637227
[TBL] [Abstract][Full Text] [Related]
47. Obesity Suppresses Estrogen Receptor Beta Expression in Breast Cancer Cells via a HER2-Mediated Pathway.
Bowers LW; Wiese M; Brenner AJ; Rossi EL; Tekmal RR; Hursting SD; deGraffenried LA
PLoS One; 2015; 10(12):e0145452. PubMed ID: 26709918
[TBL] [Abstract][Full Text] [Related]
48. EphB4 tyrosine kinase stimulation inhibits growth of MDA-MB-231 breast cancer cells in a dose and time dependent manner.
Barneh F; Moshayedi M; Mirmohammadsadeghi H; Haghjooy-Javanmard S; Sabzghabaee AM; Badri S
Dis Markers; 2013; 35(6):933-8. PubMed ID: 24427781
[TBL] [Abstract][Full Text] [Related]
49. Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer.
Jerjees DA; Alabdullah M; Green AR; Alshareeda A; Macmillan RD; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2014 Jun; 145(2):317-30. PubMed ID: 24744091
[TBL] [Abstract][Full Text] [Related]
50. Mycophenolic acid potentiates HER2-overexpressing SKBR3 breast cancer cell line to induce apoptosis: involvement of AKT/FOXO1 and JAK2/STAT3 pathways.
Aghazadeh S; Yazdanparast R
Apoptosis; 2016 Nov; 21(11):1302-1314. PubMed ID: 27651367
[TBL] [Abstract][Full Text] [Related]
51. Oxyresveratrol drives caspase-independent apoptosis-like cell death in MDA-MB-231 breast cancer cells through the induction of ROS.
Sunilkumar D; Drishya G; Chandrasekharan A; Shaji SK; Bose C; Jossart J; Perry JJP; Mishra N; Kumar GB; Nair BG
Biochem Pharmacol; 2020 Mar; 173():113724. PubMed ID: 31756327
[TBL] [Abstract][Full Text] [Related]
52. EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.
Masood R; Kumar SR; Sinha UK; Crowe DL; Krasnoperov V; Reddy RK; Zozulya S; Singh J; Xia G; Broek D; Schönthal AH; Gill PS
Int J Cancer; 2006 Sep; 119(6):1236-48. PubMed ID: 16615113
[TBL] [Abstract][Full Text] [Related]
53. High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion.
Lehtinen L; Ketola K; Mäkelä R; Mpindi JP; Viitala M; Kallioniemi O; Iljin K
Oncotarget; 2013 Jan; 4(1):48-63. PubMed ID: 23295955
[TBL] [Abstract][Full Text] [Related]
54. Antiangiogenic 1-Aryl-3-[3-(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas Inhibit MCF-7 and MDA-MB-231 Human Breast Cancer Cell Lines Through PI3K/Akt and MAPK/Erk Pathways.
Machado VA; Peixoto D; Queiroz MJ; Soares R
J Cell Biochem; 2016 Dec; 117(12):2791-2799. PubMed ID: 27152982
[TBL] [Abstract][Full Text] [Related]
55. C-FLIP(L) contributes to TRAIL resistance in HER2-positive breast cancer.
Zang F; Wei X; Leng X; Yu M; Sun B
Biochem Biophys Res Commun; 2014 Jul; 450(1):267-73. PubMed ID: 24909691
[TBL] [Abstract][Full Text] [Related]
56. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.
Noren NK; Lu M; Freeman AL; Koolpe M; Pasquale EB
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5583-8. PubMed ID: 15067119
[TBL] [Abstract][Full Text] [Related]
57. Phytoestrogens induce apoptosis via extrinsic pathway, inhibiting nuclear factor-kappaB signaling in HER2-overexpressing breast cancer cells.
Seo HS; Choi HS; Choi HS; Choi YK; Um JY; Choi I; Shin YC; Ko SG
Anticancer Res; 2011 Oct; 31(10):3301-13. PubMed ID: 21965740
[TBL] [Abstract][Full Text] [Related]
58. GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer.
Bhat RR; Yadav P; Sahay D; Bhargava DK; Creighton CJ; Yazdanfard S; Al-Rawi A; Yadav V; Qin L; Nanda S; Sethunath V; Fu X; De Angelis C; Narkar VA; Osborne CK; Schiff R; Trivedi MV
Breast Cancer Res Treat; 2018 Jul; 170(2):279-292. PubMed ID: 29574636
[TBL] [Abstract][Full Text] [Related]
59. Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers.
Young CD; Arteaga CL; Cook RS
Breast Cancer Res; 2015 Dec; 17():148. PubMed ID: 26637440
[TBL] [Abstract][Full Text] [Related]
60. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
